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Background: Pentoxifylline is a methylxanthine derivative with significant anti-inflammatory, anti-fibrotic, and
anti-proliferative properties. Studies have shown that pentoxifylline may have renoprotective effects in patients with
diabetic nephropathy. However, most of these studies were limited by small sample sizes. Therefore, we investigated
whether pentoxifylline could reduce proteinuria in patients with diabetic nephropathy and residual proteinuria who
received an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB). We also studied
the effects of pentoxifylline on glycemic control, insulin resistance, and inflammatory parameters.
Methods: This was a prospective, randomized double-blind, placebo-controlled, multi-center study. A total of 174
patients with type 2 diabetes and albuminuria (>30 mg/g of creatinine) who were taking the recommended dosage of
ACEI or ARB for > 6 months and receiving conventional therapy for diabetes were randomly assigned to receive
pentoxifylline (1200 mg, daily; n = 87) or a placebo (n = 87) for 6 months. The endpoints were the effects of pentoxifylline
on proteinuria, renal function, glucose control, and inflammatory parameters.
Results: The percentage changes in proteinuria from baseline in the pentoxifylline and placebo groups were a decrease
of 23 % and 4 %, respectively (p = 0.012). In addition, significant reductions in fasting plasma glucose, glycated
hemoglobin, and insulin resistance according to the homeostasis model assessment were observed in the
pentoxifylline group compared to those in the placebo group. However there was no significant difference in
serum tumor necrosis factor (TNF)-α between the groups.
Conclusions: Pentoxifylline therapy reduced proteinuria and improved glucose control and insulin resistance
without significant change of serum TNF-α in patients with type 2 diabetic nephropathy. Therefore, pentoxifylline is a
potential therapeutic alternative for treating diabetes and diabetic nephropathy.
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The incidence of diabetic nephropathy continues to in-
crease worldwide in association with the sweeping rise
in diabetes. In Korea, a rise in the number of patients
with end-stage renal disease undergoing dialysis, which
is the main contributor to the increasing prevalence of
diabetic nephropathy, has been reported [1]. Thus, early
detection and the effective management of diabetic ne-
phropathy are needed to delay or prevent the progression
of chronic kidney disease. Several factors are involved in
the pathophysiology of diabetic nephropathy, including
metabolic and hemodynamic alterations, oxidative stress,
inflammation, and activation of the renin-angiotensin sys-
tem (RAS) [2, 3]. Until now, blocking the RAS with an
angiotensin-converting enzyme inhibitor (ACEI) or angio-
tensin II receptor blocker (ARB) was generally accepted as
the standard treatment to delay the progression of diabetic
nephropathy [4]. Although the treatment with ACEIs or
ARBs decreases proteinuria, the risk of residual protein-
uria remains; and these drugs do not stop the progression
of diabetic nephropathy completely [5]. Therefore, many
studies have been conducted using novel agents targeting
their anti-inflammatory, anti-oxidant, anti-fibrotic, and
intracellular modulatory properties [2].
The first use of pentoxifylline as a potential treatment
for diabetic nephropathy occurred in the early 1980s [6].
Pentoxifylline is a non-selective phosphodiesterase inhibi-
tor and adenosine receptor antagonist [7]. This methyl-
xanthine derivative has been used primarily to treat
peripheral vascular disease due to its hemorheologic and
anti-inflammatory properties [8]. These properties are also
associated with the pathogenesis of diabetic nephropathy;
therefore, there has been interest in using pentoxifylline to
treat diabetic nephropathy. Some studies reported that
pentoxifylline reduced proteinuria in subjects with dia-
betes, while other studies have failed to show a clear-cut
anti-proteinuric effect of pentoxifylline [9–15]. Another
limitation is that most studies favoring pentoxifylline were
poorly designed, with small sample sizes and flawed meth-
odology, so evidence to support the use of pentoxifylline
to treat diabetic nephropathy is insufficient [16].
In addition, studies examining the glycemic control effect
of pentoxifylline have been reported intermittently since
the 1970s [17–23]. Pentoxifylline exerts beneficial effects
on obesity, glucose metabolism, and insulin resistance in
patients with nonalcoholic fatty liver disease, which shares
a common pathogenesis with diabetes, including insulin
resistance, oxidative stress, and inflammation in recent
studies [24, 25].
Therefore, we investigated whether pentoxifylline could
reduce proteinuria in patients with diabetic nephropathy
and residual proteinuria despite receiving an ACEI or ARB.
We also studied the effects of pentoxifylline on glycemic
control, insulin resistance, and inflammatory parameters.Methods
Study subjects
In total, 174 subjects (103 males, 71 females; age 63.8 ±
9.6 years) were included in this study. Patients with type 2
diabetes who were ≥ 20 years old and who met the follow-
ing criteria were eligible to participate: spot urinary albu-
min/creatinine (Cr) ratio > 30 mg/g on two consecutive
measurements without other kidney or renal tract disease;
blood pressure (BP) < 150/100 mmHg; treatment with an
ACEI or ARB for > 6 months; glycated hemoglobin
(HbA1c) < 10 %; and no drug changes within 4 weeks of
randomization for this study.
The exclusion criteria included serum Cr > 2.0 mg/dL;
a history of systemic inflammatory, immunological, or
malignant diseases or cardiovascular disease in the pre-
vious 6 months; immunosuppressive or herb medication
treatments; the use of pentoxifylline, cilostazol, ibudilast,
or sildenafil citrate in the past 3 months; pregnancy, breast-
feeding, or planning to become pregnant; and more than
three-fold above the upper normal limits for aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT).
Study design
This was a prospective, randomized double-blind, placebo-
controlled, multi-center study.
The study protocol was approved by the Institutional
Review Board and ethics committee of the Ajou Univer-
sity School of Medicine (Suwon, Republic of Korea) and
the Korean Ministry of Food and Drug Safety. This trial
was registered with the US National Institutes of Health
Clinical Trials (NCT01382303). All subjects gave in-
formed consent. A total of 174 subjects were randomly
assigned to either the pentoxifylline (Trental®, Han Dok
Inc., Korea) (n = 87) or placebo group (n = 87) according
to a computer-generated allocation system. Allocation
was concealed by enclosing assignments in sequentially
numbered, sealed opaque envelops, which were opened
only after the enrolled subjects had completed all base-
line assessments and treatment needed to be allocated.
Patients in the pentoxifylline group received 400 mg of
pentoxifylline three times daily for 6 months, whereas
the placebo group received identical starch tablets on
the same schedule. The standard dose of pentoxifylline
is 400 mg three times daily, which was used in previous
studies that reported an anti-proteinuria effect of pen-
toxifylline [11, 26].
Patients were not allowed to change their medication
during the study and were asked not to alter their current
diet or physical activity. Participants were followed up
after 3 and 6 months during the treatment period to
evaluate the outcome measurements. Also, 1 month after
the discontinuation of the study drug, urine samples were
taken for measurement of proteinuria and albuminuria.
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Body mass index (BMI) was calculated as weight (kg)/
height squared (m2). Arterial BP was measured twice
with a 5 min interval, using a standard mercury sphyg-
momanometer with the patient in a sitting position after
a 5 min rest. The measurements were recorded at base-
line and at the 3 and 6 months follow up visits.
Blood samples and single- first morning void urine
samples were collected before breakfast in the morning
after an 8–12-h overnight fast. The samples were col-
lected in sterile tubes, centrifuged at 3000 × g for 10 min
at 4 °C, and stored at –70 °C until analysis. Plasma glu-
cose, insulin, HbA1c, serum Cr, AST, ALT, r-glutamyl
transpeptidase(r-GT), serum high-sensitivity C-reactive
protein (hs-CRP), serum and urine tumor necrosis factor
(TNF)-α, and urinary protein, albumin and Cr levels
were measured. All biochemical analyses were per-
formed by Seoul Clinical Laboratories (Seoul, Republic
of Korea).
Plasma glucose levels were measured with an automated
enzymatic method. Insulin concentrations were measured
with a microparticle enzyme immunoassay kit (Abbott,
Mannheim, Germany) in subjects who were not receiving
insulin treatment. Insulin resistance was evaluated accord-
ing to the homeostatic model assessment insulin resistance
(HOMA-IR) index ([fasting serum insulin (μIU/mL) × fast-
ing serum glucose (mmol/l)]/22.5) [27]. The HbA1c con-
centration was determined by a turbidimetric inhibition
immunoassay (Roche, Mannheim, Germany). Serum Cr
and urine protein concentrations were measured using a
standard colorimetric method [28]. Urine albumin concen-
trations were quantified by an immunoturbidimetric assay
and urine Cr was measured using the Jaffe kinetic assay.
The magnitude of urinary protein and albumin excretion
was represented by the protein/Cr ratio and albumin/Cr
ratio, respectively, in single-void urine samples [29]. The
estimated glomerular filtration rate (eGFR) was determined
by the simplified Modification of Diet in Renal Disease
formula [30].
Serum AST and ALT levels were measured using the
kinetic ultraviolet method according to the International
Federation of Clinical Chemistry. Serum r-GT was mea-
sured using an enzymatic colorimetric assay with an
automatic analyzer (Hitachi, Tokyo, Japan).
Measurement of inflammatory parameters
Serum TNF-α concentrations were measured using a com-
mercial available high-sensitivity enzyme-linked immuno-
sorbent assay (ELISA) kit (R&D Systems, Minneapolis,
MN, USA). The lower limit of detection is 0.106 pg/mL,
and the intra- and inter-assay coefficients of variation of
the assay were 3.1 and 7.2 %, respectively.
The urinary TNF-α values were below or just at the
threshold of detection using a human TNF-α PlatinumELISA kit (eBioscience, San Diego, CA, USA); therefore,
the values were measured again using a high-sensitivity
ELISA kit (R&D Systems).
Serum hs-CRP levels were measured using a latex ag-
glutination method and an automatic analyzer (Hitachi,
Tokyo, Japan).
Outcome measures
The primary end point was the percentage change from
baseline to final on-treatment in proteinuria with pen-
toxifylline compared with the placebo group. Secondary
end points included the percentage change of albumin-
uria and the mean change of eGFR, serum Cr, fasting
glucose, HbA1c, HOMA-IR, hs-CRP, and serum TNF-α
from baseline to final on-treatment.
Statistical analyses
We calculated the necessary sample size based on a
study of the combined effect of pentoxifylline and an
ARB on proteinuria vs. an ARB only [31]. To detect a
25 % relative change with a Type 1 error rate of 0.05 and
with a coefficient of variation of 0.55, the minimum re-
quired sample size for 90 % power was 69 in each group,
and 87 after considering a 20 % drop-out rate.
All efficacy and safety analyses were conducted on the
data in accordance with the intention-to-treat principle.
Continuous variables are expressed as the mean ± standard
deviation or median (interquartile range), and categorical
variables are expressed as frequencies (percentages). The
independent t-test or Mann–Whitney U-test was used to
compare continuous variables between the groups accord-
ing to the normality assumption. The χ2 test was imple-
mented for categorical data, as appropriate.
The Mann–Whitney U-test was used to analyze the per-
centage change of proteinuria/albuminuria from baseline
to final on-treatment between the placebo and the pentox-
ifylline groups. The remaining end points between the pla-
cebo and pentoxifylline groups were measured using the
independent t-test. Changes within the groups were ana-
lyzed by paired t-tests at baseline and after 6 months of
treatment.
Multivariate regression analysis was used to evaluate
the independent association between pentoxifylline and
the change of HbA1c. The correlation between changes
in proteinuria and HbA1c from baseline to the end of
the study was analyzed using Pearson correlation tests.
All statistical tests were two-tailed, and p-values < 0.05
were considered significant. All analyses were performed
using SPSS for Windows ver. 19 (SPSS, Chicago, IL, USA).
Results
The disposition of the patients in the trial is shown in
Fig. 1. A total of 174 of the 196 initially screened patients
met the eligibility criteria and were randomly assigned to
Fig. 1 Flow diagram of the study
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in the placebo and seven in the pentoxifylline group were
lost to follow-up. Five subjects in the placebo group dis-
continued the study due to adverse events (AEs), and one
subject withdrew for personal reasons. Thirteen subjects
discontinued the study due to AEs in the pentoxifylline
group; one subject was removed due to an overdose viola-
tion, and nine subjects withdrew for personal reasons. In
total, 8 patients were excluded because urine data were
unavailable and the 122 remaining were evaluated. The
baseline demographic and clinical characteristics of the
two groups were similar (Tables 1 and 2). No significant
differences were observed in BP, renal function, urinary
protein and albumin excretion, or metabolic parameters,
except HbA1c. The pentoxifylline group had a higher
HbA1c level than the placebo group (7.5 ± 0.9 vs. 7.2 ±
0.8 % (59 ± 10 vs. 56 ± 9 mmol/mol), p = 0.043). The
urinary TNF-α concentration was below or just at the
threshold of detection in all patients at baseline and
remained so throughout the study (data not shown).
At the 3- and 6-month treatment time points, protein-
uria in the pentoxifylline group decreased significantly
compared to that in the placebo group (3 months: 19 %
decrease (−36 to 7) vs. 9 % increase (−28 to 35), p =
0.004; 6 months: 23 % decrease (−50 to 10) vs. 4 % de-
crease (−30 to 40), p = 0.012) (Fig. 2). The pentoxifylline
group showed a trend toward decreased albuminuria
(3 months: 15 % decrease (−38 to 15) vs. 9 % increase
(−30 to 44), p = 0.074; 6 months: 19 % decrease (−57 to
30) vs. 3 % increase (−41 to 57), p = 0.072).Subgroup analyses were performed to determine whether
baseline proteinuria and HbA1c influenced any change in
proteinuria. In the subjects with microalbuminuria (n = 87),
pentoxifylline group showed a significant decrease in pro-
teinuria and albuminuria compared to those in the placebo
group (proteinuria: 26 % decrease (−47 to 9) vs. 4 % de-
crease (−25 to 30), p = 0.012; albuminuria: 36 % decrease
(−58 to 33) vs. 12 % increase (−41 to 93), p = 0.029). How-
ever, no significant differences were observed between the
groups in the subjects with macroalbuminuria (n = 35,
proteinuria: 23 % decrease (−54 to 21) vs. 5 % decrease
(−43 to 44), p = 0.405; albuminuria: 18 % decrease (−40
to 29) vs. 20 % decrease (−46 to 50), p = 0.947). In
addition, there was no significant difference in primary
outcome between the groups according to baseline median
HbA1c levels (HbA1c ≤ 7.175 (n = 61), 29 % decrease (−52
to 8) vs. 5 % decrease (−30 to 44), p = 0.112; HbA1c >7.175
(n = 61), 22 % decrease (−47 to 17) vs. 2 % decrease (−33 to
28), p = 0.106).
To evaluate whether long term anti-proteinuric effects
of pentoxifylline remained 1 month after discontinuation
of treatment, we collected urine samples. No significant
change in proteinuria and albuminuria was observed be-
tween the groups (proteinuria: pentoxifylline vs. placebo
19 % decrease (−43 to 49) vs. 7 % decrease (−36 to 23),
p = 0.491; albuminuria 10 % decrease (−47 to 50) vs. 6 %
decrease (−45 to 41), p = 0.936, Fig. 2).
Although eGFR in the pentoxifylline group declined sig-
nificantly after 3 months of treatment compared to that of
the placebo group, there were no significant differences







Age (years) 63.8 ± 9.4 63.7 ± 10.1 0.972
Sex (M/F) 56/31 47/40 0.217
Duration of diabetes (years) 12.6 ± 8.1 12.4 ± 8.3 0.917
BMI (kg/m2) 25.4 ± 3.5 26.0 ± 3.1 0.259
Systolic BP (mmHg) 127.8 ± 11.9 127.6 ± 14.1 0.938
Diastolic BP (mmHg) 74.0 ± 8.9 76.2 ± 10.4 0.141
Statin treatment (%) 56.3 50.0 0.448
Diabetes medication
Sulfonylurea (%) 59.8 62.8 0.755
Metformin (%) 83.9 86.0 0.832
Thiazolidinedione (%) 5.7 7.0 0.766
DPP-4 inhibitor (%) 25.3 25.6 1.000
Insulin (%) 13.8 16.3 0.676
Data are presented as means ± standard deviation (SD), or
numbers (percentage)
BMI body mass index, BP blood pressure, DPP-4 dipeptidyl peptidase 4
The independent t-test was used to compare continuous variables between
the groups. The χ2 test was implemented for categorical data
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(eGFR: −1.05 ± 18.20 vs. −3.59 ± 14.20, p = 0.391, Fig. 2).
In addition, no significant changes in the serum Cr level
were observed between the groups (pentoxifylline vs. pla-







Serum Cr (mg/dL) 0.9 ± 0.3 0.9 ± 0.2 0.165
Urinary Cr (mg/dL) 103 (72-136) 86 (61-122) 0.176
eGFR (ml/min per 1.73 m2) 85.4 ± 27.0 88.8 ± 24.8 0.401
Proteinuria (mg/g) 395 (229–714) 371 (218–610) 0.689
Albuminuria (mg/g) 203 (88-513) 143 (71-315) 0.201
Fasting plasma glucose (mg/dL) 140 ± 35 138 ± 35 0.795
HbA1c (%) 7.2 ± 0.8 7.5 ± 0.9 0.043
AST(U/L) 26.5 ± 14.9 24.8 ± 8.7 0.368
ALT(U/L) 26.5 ± 18.0 26.3 ± 12.4 0.910
r-GT(U/L) 39.0 ± 36.2 35.4 ± 32.9 0.515
hs-CRP (mg/L) 1.7 ± 2.3 1.8 ± 2.8 0.667
Serum TNF-α (pg/mL) 1.4 ± 1.4 1.6 ± 2.8 0.570
Data are presented as means ± standard deviation (SD) or medians
(interquartile ranges)
Cr creatinine, eGFR estimated glomerular filtration rate, HbA1c glycated
hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase,
r-GT r-glutamyl transpeptidase, hs-CRP high-sensitivity C-reactive protein,
TNF tumor necrosis factor
The independent t-test or Mann–Whitney U-test was used to compare continuous
variables between the groups according to the normality assumptionBMI, systolic BP, and diastolic BP did not differ signifi-
cantly between the two groups (Table 3). Treatment with
pentoxifylline significantly reduced the HbA1c level, fast-
ing glucose level, and HOMA-IR value compared to those
in the placebo group (p < 0.05). HbA1c decreased signifi-
cantly in the pentoxifylline group (from 7.6 ± 0.9 to 7.2 ±
0.9 % (59 ± 10 to 55 ± 10 mmol/mol), p < 0.05), without a
significant change in the placebo group. To confirm the
glucose-lowering effect of pentoxifylline, we performed
multivariate regression analysis with the change in HbA1c
as the dependent variable and clinical parameters as inde-
pendent variables. This indicated that pentoxifylline treat-
ment was an independent factor associated with a change
of HbA1c after adjusting for baseline HbA1c, age, sex,
change in BMI, and duration of diabetes (p = 0.003).
Figure 3 shows the relationship between the changes in
proteinuria and HbA1c from baseline to 6 months of
treatment. There was no significant correlation within
either group (Fig. 3). No significant changes in hs-CRP,
serum TNF-α, AST, ALT, r-GT were observed in either
group during the study.
The frequency of AEs was higher in the pentoxifylline
group than in the placebo group (Table 4). No drug-
related serious AEs were reported. The major AEs in the
pentoxifylline group were gastrointestinal disturbances
such as dyspepsia, nausea, vomiting, gastric reflux, diarrhea,
constipation and headache. Drug-related or non-drug-
related AEs led to discontinuing the medication in 18 pa-
tients: five in the placebo group (femoral fracture, lumbar
spine fracture, acute hepatitis, nausea, and hyperglycemia
with nausea) and 13 in the pentoxifylline group (ten
with gastrointestinal disturbances, headache, dizziness,
and flushing).Discussion
Proteinuria is an important predictor of end stage renal
disease in patients with diabetic nephropathy [32]. Redu-
cing proteinuria is effective in delaying the progression
of chronic renal disease, as well as decreasing cardiovas-
cular morbidity and mortality [33, 34].
We found that a 6-month pentoxifylline treatment
added to a RAS inhibitor reduced proteinuria, the HbA1c
level, and the HOMA-IR value compared with placebo.
No significant relationship was observed between the
changes of proteinuria and the change in HbA1c. There-
fore, the additive anti-proteinuric effect of pentoxifylline
was independent of improved glycemic control. Our re-
sults confirm reports of an anti-proteinuric effect of pen-
toxifylline in patients with diabetic nephropathy and show
the beneficial effects of maintaining glucose homeostasis
[11, 12, 35].
Pentoxifylline treatment showed a trend of reducing
albuminuria, however displayed significant reductions of
A C
B
Fig. 2 Changes in proteinuria and renal function induced by placebo or pentoxifylline. a Proteinuria change was the percentage change from
baseline and expressed as median with interquartile range. b Albuminuria change was the percentage change from baseline and expressed as
median with interquartile range. c The eGFR change was the change from baseline and expressed as mean ± standard deviation (SD). eGFR,
estimated glomerular filtration rate. P-values are for comparisons of each variable between the placebo and pentoxifylline groups at the
corresponding time points
Han et al. Diabetology & Metabolic Syndrome  (2015) 7:64 Page 6 of 9both proteinuria and albuminuria in microalbuminuria
subgroup compared to those in the placebo group. There-
fore, we think heterogeneity in subjects’ characteristics in-
fluences the results of albuminuria. Interestingly, our
results are contrary to a meta-analysis by McCormick
et al. (2008), which showed that pentoxifylline decreased
proteinuria in patients with macroalbuminuria, but not
with microalbuminuria [9]. However, our study consisted
of a small proportion of subjects with macroalbuminuria,
which could be the reason for the differences compared
with the previous study.
Whether the additive anti-proteinuric effect of pentox-
ifylline remains after discontinuation has not been dem-
onstrated to date. We found that the anti-proteinuric
effect of pentoxifylline was not sustained 1 month after
drug discontinuation.No significant difference in eGFR was observed be-
tween the groups. Our trial included subjects with
predominantly preserved renal function (serum Cr ≤
2.0 mg/dL). By contrast, most studies showing beneficial
effects of pentoxifylline on eGFR enrolled mostly patients
with advanced chronic kidney disease [13, 15, 35]. An in-
vestigation of the effect of pentoxifylline on the eGFR in
lower-risk patients will require a longer follow-up period
to observe differences. In addition, there was no significant
difference in serum Cr between the groups. Although
Rodriguez-Moran et al. (2006) reported that pentoxifylline
significantly reduced serum Cr levels, a recent meta-
analysis of six randomized controlled trials showed results
similar to ours; i.e., that combining pentoxifylline with
RAS inhibitors did not significantly change the serum
Cr levels [36, 37].
Table 3 Changes in metabolic parameters induced by the






BMI (kg/m2) 0.22 ± 1.75 −0.25 ± 0.80 0.079
Systolic BP (mmHg) 3.9 ± 18.3 1.3 ± 15.7 0.417
Diastolic BP (mmHg) 0.3 ± 11.8 1.8 ± 10.9 0.473
HbA1c (%) 0.09 ± 0.72 −0.34 ± 0.74 0.002
Fasting plasma glucose (mg/dL) 8.4 ± 37.4 −10.0 ± 38.9 0.009
HOMA-IRa 0.24 ± 2.61 −0.79 ± 2.03 0.041
Hs-CRP (mg/L) 0.70 ± 4.33 0.51 ± 4.32 0.818
Serum TNF-α (pg/mL) 0.14 ± 0.71 −0.24 ± 3.11 0.322
AST(U/L) 0.33 ± 13.33 −1.31 ± 7.84 0.432
ALT(U/L) −0.30 ± 14.38 −1.37 ± 8.75 0.637
r-GT(U/L) 1.19 ± 25.27 −3.90 ± 8.88 0.126
Data expressed as the means ± standard deviation (SD). P-values are for
comparing the absolute change in each variable between the placebo and
pentoxifylline groups
aHOMA-IR was measured only in subjects who were not receiving insulin
treatment, placebo (n = 58), pentoxifylline (n = 39)
BMI body mass index, BP blood pressure, HbA1c glycated hemoglobin, HOMA-IR
homeostatic model assessment insulin resistance, hs-CRP high-sensitivity
C-reactive protein, TNF tumor necrosis factor, AST aspartate aminotransferase,
ALT alanine aminotransferase, r-GT, r-glutamyl transpeptidase
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of the 24-h urine protein collection test on the basis of
the assumption that the urine protein excretion rate, which
is proportional to the urine Cr excretion rate, is relatively
constant throughout the day [29]. There was no significant
difference in urinary Cr levels at baseline and after treat-
ment between the two groups.
The mechanisms underlying the anti-proteinuric ef-
fects of pentoxifylline remain unknown, although someFig. 3 The relationship between the change in proteinuria and HbA1c frompossibilities can be discussed. The first is antagonist ac-
tion on adenosine 2 receptors that modulate GFR and
the renal action of atrial natriuretic factor [10, 33]. Second,
the hemorheologic effect of pentoxifylline promotes bene-
ficial changes in blood flow by improving blood fluidity in
the peritubular plexus and reducing overload of low-
molecular-weight proteins into the proximal tubule, ac-
tions that reduce intra-glomerular pressure [34]. Finally,
pentoxifylline decreases intrarenal inflammation based on
its anti-TNF-α properties [35, 38].
Contrary to our expectations, we failed to observe any
change in serum TNF-α associated with pentoxifylline
treatment. Similarly, pentoxifylline failed to significantly
reduce serum TNF-α levels in patients with chronic
kidney disease [38]. A meta-analysis of pentoxifylline
for treating nonalcoholic fatty liver disease also failed
to show changes in serum levels [24]. The reasons for
this inconsistent result are unclear; however, the lack of
change in circulating TNF-α might not correlate with
tissue levels.
We noted beneficial effects of pentoxifylline on glucose
control and insulin resistance (HOMA-IR). Earlier studies
of the effects of pentoxifylline on glucose metabolism
showed glucose-lowering effects by stimulating insulin se-
cretion by increasing intracellular cAMP levels [17, 19].
Pentoxifylline potentiates amino acid- and glibenclamide-
induced insulin secretion [17, 18]. Raptis et al. (1987) re-
ported that 14 days of the daily administration of 1200 mg
of pentoxifylline led to a decrease in blood glucose and a
smoothing of glucose fluctuations in patients with type 2
diabetes [19]. They suggested that pentoxifylline aug-
mented insulin secretion and improved peripheral glucose
utilization. In another study, administering pentoxifyllinebaseline. a placebo group, b pentoxifylline group





Overall summary of patients with an AE, n (%)
One or more AE, n (%) 20 (23.0) 27 (31.0)
One or more drug-related AE, n (%) 12 (13.8) 23 (26.4)
AE leading to discontinuation 5 (5.7) 13 (14.9)
Patients with AEs of ≥3 % in any group, n (%)
Dyspepsia 1 (1.1) 7 (8.0)
Nausea/vomiting 2 (2.3) 5 (5.7)
Gastric reflux 3 (3.4) 5 (5.7)
Diarrhea 0 (0.0) 2 (2.3)
Constipation 0 (0.0) 1 (1.1)
Headache 1 (1.1) 3 (3.4)
AE adverse event
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healthy subjects [20].
Pentoxifylline has anti-inflammatory and anti-oxidant
abilities, which play important roles in the pathogenesis
of diabetes [22, 23, 39, 40]. Studies have shown that pen-
toxifylline improves glucose control by downregulating
the pro-inflammatory cytokine-mediated nitric oxide syn-
thase pathway in an animal model of diabetes [21, 22].
Garcia et al. reported that pentoxifylline has glucose
lowering effects, at least partly related to the inhibition
of ATP-sensitive K+ and suppression of TNF-α, inducible
nitric oxide synthase and cyclooxygenase-2 in the pan-
creas of diabetic rats [23].
Recently, a few studies reported the effects of pentoxifyl-
line on glucose and insulin resistance in patients with
nonalcoholic fatty liver disease, which has a somewhat
similar pathogenesis as diabetic nephropathy. In these
studies, 6 months of pentoxifylline therapy showed a
significant reduction in HOMA-IR as well as in liver
enzymes [41, 42]. In a meta-analysis of randomized
double-blind placebo-controlled studies, pentoxifylline
treatment led to a significant reduction in glucose [24].
The underlying mechanism for the glucose-lowering effect
of pentoxifylline needs to be investigated in future studies.
Although our study was well-designed, it has limitations.
First, there was an unexpectedly high rate of AEs in our
study due to pentoxifylline treatment, which limited ad-
herence to the therapy. Gastrointestinal disturbances
are well-recognized potential AEs of pentoxifylline. These
effects are dose-related and dosage form-related, with a re-
ported higher frequency in patients taking a higher dosage
and in those taking an immediate-release form compared
to those taking an extended-release form. Because our
subjects could not tolerate doses of 1200 mg/day of
immediate-release pentoxifylline compared to other study
populations, we hypothesize that dosage up-titration withan extended-release form may decrease the rate of AEs
[35, 43]. Although the unexpectedly high dropout rate in
the pentoxifylline group meant that the study did not
reach the desired statistical power, the effects of pentoxi-
fylline on proteinuria were still positive. Second, although
the patients were asked not to alter their current diet and
physical activity, we did not evaluate the potential role of
these factors in the results. Third, the follow-up period
was relatively short. Finally, as we used only a single first
morning void urine sample, instead of three consecutive
first morning void urine samples, the measurements of
proteinuria may be less accurate.
Conclusions
In conclusion, adding pentoxifylline to an ACEI or ARB re-
duced proteinuria in Korean patients with type 2 diabetic
nephropathy and exerted beneficial effects on glucose con-
trol and insulin resistance. Therefore, pentoxifylline is a
potential therapeutic alternative for treating diabetes and
diabetic nephropathy.
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